Latest Us Market News

Thrive Tribe Technologies reported a $186,000 net operating cash outflow in Q2 FY26, offset by a $300,000 equity raise to fund growth initiatives and operational expansion.

Hydrix Limited reported $2.3 million in revenue for Q2 FY26 and secured a $2.5 million initial contract with SynCardia Systems to develop a fully implantable artificial heart, setting a positive tone for 2026.

GCM Corporation’s latest quarterly report confirms its VHD thermal management technology outperforms copper and aluminium, while commercial and US listing plans gain momentum.

4DMedical Limited has responded to ASX queries over its announcements of commercial agreements with leading US academic medical centres, clarifying its disclosure approach and denying ramping allegations ahead of a $150 million capital raise.

Bubs Australia reports a 14% increase in half-year revenue, powered by a 47% jump in US sales, while other regions face challenges. The company remains optimistic about FDA approval and market recovery in H2 FY26.

Tungsten Mining NL reports a robust December quarter marked by soaring tungsten prices, a landmark scoping study at Mt Mulgine, and a $53 million capital raise, positioning the company for accelerated development.

ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.

HITIQ has made significant strides in expanding its concussion management technology, PROTEQT©, into North America and Australian retail, backed by strong research partnerships and a successful capital raise.

Energy Transition Minerals Ltd has raised A$24.7 million through a strongly supported placement to advance its Kvanefjeld Project and strategic acquisitions, positioning itself for growth amid ongoing arbitration challenges.

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.

Latrobe Magnesium has resolved a critical manufacturing defect at its Demonstration Plant, enabling Magnesium Oxide production to resume, while securing key financial support for its commercial expansion plans.

Artrya Limited has converted three US foundation partners into commercial customers, generating its first fee-per-scan revenues, while progressing FDA clearance for its Salix Coronary Flow module and expanding its clinical study network.